Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel | Zendy

Filippo Francini | Zendy; Alessandra Pascucci | Zendy; Edoardo Francini | Zendy; Gianluca Bargagli | Zendy; Raffaele Conca | Zendy; Antonella Licchetta | Zendy; Giandomenico Roviello | Zendy; Ignazio Martellucci | Zendy; G. Chiriacò | Zendy; Salvatora Tindara Miano | Zendy; G. Marzocca | Zendy; Antonio Manganelli | Zendy; Roberto Ponchietti | Zendy; Vinno Savelli | Zendy; Roberto Petrioli | Zendy

Open Access

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Author(s) -

Filippo Francini,

Alessandra Pascucci,

Edoardo Francini,

Gianluca Bargagli,

Raffaele Conca,

Antonella Licchetta,

Giandomenico Roviello,

Ignazio Martellucci,

G. Chiriacò,

Salvatora Tindara Miano,

G. Marzocca,

Antonio Manganelli,

Roberto Ponchietti,

Vinno Savelli,

Roberto Petrioli

Publication year - 2011

Publication title -

prostate cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.377

H-Index - 11

eISSN - 2090-3111

pISSN - 2090-312X

DOI - 10.1155/2011/258689

Subject(s) - medicine , docetaxel , bevacizumab , tolerability , prostate cancer , regimen , chemotherapy , oncology , urology , cancer , surgery , adverse effect

Background . The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods . Treatment consisted of D 30 mg/m 2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks. Results . Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated. Conclusion . Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research